Femara (Letrozole) Versus Placebo for Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Summary

Primary Objective: 1\. Evaluate the efficacy of letrozole to increase the duration of progression-free survival (defined as time to earliest occurrence of local or distant recurrence or clinically significant elevation in CA-125) when used as adjuvant treatment after completion of primary surgery and first line platinum containing chemotherapy in patients with optimally debulked (\< 1 cm residual disease) stage IIA-IIIC ovarian, fallopian tube, or primary peritoneal cancer. Secondary Objective: 1\. Observe the incidence of local and distant recurrences.

Timeline

Start

2008-03

Primary completion

2008-09

Completion

2008-09

Outcome

Outcome not reported

Stopped: “Study halted with no registration, the drug company sponsor withdrew support.”

Drugs

Indications